Recombinant betatrophin (Angptl ‑8/lipasin) ameliorates streptozotocin‑induced hyperglycemia and β‑cell destruction in neonatal rats.

Recombinant betatrophin (Angptl‑8/lipasin) ameliorates streptozotocin‑induced hyperglycemia and β‑cell destruction in neonatal rats. Mol Med Rep. 2019 Oct 01;: Authors: Zhang D, Yu YJ, Xu FS, Yuan JH, Wang R, Zhang CS, Wang LX, Liu Y, Song LM, Liu JL, Dong J Abstract Betatrophin [also known as lipasin, angiopoietin‑like 8 (ANGPTL8), refeeding induced in fat and liver (RIFL), or hepatocellular carcinoma‑associated gene TD26], a 22‑kDa protein in the angiopoietin‑like family, is a liver‑derived hormone that promotes pancreatic β‑cell proliferation and lipid metabolism. The aim of the present study was to investigate the effect of recombinant betatrophin on β‑cell regeneration in a neonatal streptozotocin (STZ)‑induced diabetic rat model. One‑day‑old Wistar rats were injected with STZ (100 mg/kg), followed by intraperitoneal administration of betatrophin to the STZ‑injected rats for 6 days. Plasma glucose and body weight were monitored. On days 4 and 7, expression levels of pancreatic duodenal homeobox gene‑1 (PDX‑1), the Bax/B‑cell lymphoma‑2 (Bcl‑2) ratio and plasma insulin were assessed, and the β‑cell proliferation rate was determined. Pancreatic islet area and number were determined at 10 weeks. It was found that betatrophin treatment alleviated STZ‑induced hyperglycemia, elevated pancreatic expression levels of Bcl‑2, PDX‑1, plasma insulin levels and the β...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research

Related Links:

ConclusionsIn our cohort, HCV and diabetes were the main risk factors for HCC. The majority of patients was not amenable to sorafenib treatment and carries a very poor prognosis.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
Abstract Metformin, a widely prescribed anti-diabetic drug, also exerts anti-cancer effects in different types of cancers. Although a number of molecular mechanisms have been suggested, the metabolic features underlying metformin's anti-cancer activity is not fully understood enough. Because cancer cells have been known to prefer inefficient aerobic glycolysis to support their proliferation, it is important to clarify by which metformin affects metabolism to suppress the proliferation of cancer cells. Here, we report the metabolic changes induced by metformin and its relevance to the induction of apoptosis in H4II...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
Conclusion HBV-infection increased significantly the risk for cirrhosis among T2DM patients, however, not beyond the expected incremental risk among infected non-T2DM subjects. Our approach to evaluate the role of T2DM/NAFLD and HBV-infection in liver disease progression could be applied to other settings with higher HBV prevalence.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
We read with interest your letter to the editor expressing concern about using ROCK2 inhibition for diabetic cardiomyopathy (DCM) management, as it may promote tumor metastasis and disturb some physiological functions. However, the effect of ROCK2 on metastasis seems to be tumor and context specific. In fact, numerous studies reported a metastasis-promoting role for ROCK2 in tumors like gastric cancer [1] hepatocellular carcinoma [2] and osteosarcoma [3], and that ROCK2 inhibition produced beneficial effects.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
This study provides a systematic view of the synergism between genetic and diet factors in the dynamic liver cancer formation process, and indicate that overfeeding or a high-fat diet and the risk genes have a synergistic effect in causing liver cancer by affecting fatty acid metabolism and ribosome biogenesis.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionMetabolic profiling identifies distinct dysregulated metabolites in HCC patients with/without diabetes.
Source: Metabolomics - Category: Biology Source Type: research
ConclusionsThe additive risk of T2DM for HCC development was highest in patients with NASH. HCC risk may vary depending on the underlying etiology.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) is a complex chronic disease resulting from an interaction between genetic and environmental factors. The phenotype and pathophysiology of NAFLD is heterogeneous. NAFLD is a continuum of histological lesions of the liver from steatosis, Non-Alcoholic SteatoHepatitis (NASH), NASH with fibrosis, cirrhosis to hepatocellular carcinoma. The pathophysiology encompasses a dysfunction in fatty tissue (sub-cutaneous and visceral) associated with insulin-resistance and metabolic inflammation. NAFLD is a "multi-systemic" disease. Reciprocal and aggravating interact...
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research
AbstractPurpose of reviewIn this review article, we evaluate sex differences in the natural history of NAFLD and highlight distinct risk profiles of women with NAFLD, as well as unique treatment considerations and research gaps.Summary of FindingsReproductive factors, such as menopausal status, should be considered when evaluating NAFLD risk in women, as well as additional reproductive risk factors such as age at menarche, presence of polycystic ovary syndrome, and gestational diabetes. Women do appear to have lower risk for hepatocellular carcinoma from NASH, as well as lower mortality from NASH cirrhosis than men, althou...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
Nonalcoholic fatty liver disease (NAFLD) is currently among the most common causes of chronic liver disease liver disease worldwide, affecting ≥25% of the global adult population and a prevalence that exceeds 55% in individuals with type 2 diabetes mellitus.1,2 The potentially progressive form of NAFLD, nonalcoholic steatohepatitis (NASH), can advance to advanced fibrosis and cirrhosis; it is responsible for an increasing number of cases of hepatocellular carcinoma, liver transplantation, and/or death in the United States.
Source: Gastroenterology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research
More News: Cancer & Oncology | Carcinoma | Diabetes | Endocrinology | Genetics | Hepatocellular Carcinoma | Hormones | Insulin | Liver | Liver Cancer | Molecular Biology | Pancreas | Perinatology & Neonatology | Study | Urology & Nephrology